Charles Schwab
BBNX

Charles Schwab’s Beta Bionics BBNX Stock Holding History

Charles Schwab’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.23M Sell
322,467
-9,156
-3% -$135K ﹤0.01% 2577
2025
Q4 		$10.1M Buy
331,623
+931
+0.3% +$24.9K ﹤0.01% 2138
2025
Q3 		$6.57M Buy
330,692
+228,467
+223% +$4.01M ﹤0.01% 2308
2025
Q2 		$1.49M Buy
102,225
+611
+0.6% +$8.65K ﹤0.01% 2765
2025
Q1 		$1.24M Buy
+101,614
New +$1.89M ﹤0.01% 2769

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab's BBNX Position: Q1 2026 in Review

Charles Schwab reduced its Beta Bionics (BBNX) stake by 2.8% in Q1 2026, selling an estimated $135K and leaving 322,467 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Charles Schwab first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $10.1M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Charles Schwab held 322,467 shares of Beta Bionics worth $3.23M as of Q1 2026.
  • Charles Schwab sold 9,156 Beta Bionics shares in Q1 2026, an estimated $135K.
  • Beta Bionics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #2577 holding.
  • Charles Schwab first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Charles Schwab's Beta Bionics position peaked at $10.1M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.